There would seem to be some benefit in having a new team,...

There would seem to be some benefit in having a new team, especially for negotiations with DRL. They will be less constrained by history. As to marketing HyAct and VAST, I am less sure, it is intellectual property and, without the intellects around, it might make things harder.

I agree with Caketin that the sales and profit figures for fondaparinux sodium are difficult to reconcile. It is about time someone published the real value and volume figures, rather than DRL's interpretation.

I find it hard to accept that ACL was not aware of the market strategy being adopted by DRL, the extent of the discounting, and its impact on the competition. I understand that in pharmacology marketing data is extensive and, while not public, is available to subscribers (like DRL).

On a personal note my losses are still less than 6 figures, a lot of money, but not a disaster. I shall stick around to find out what happens.